Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

Annals of the New York Academy of Sciences

Volumn 1407, Issue 1, 2017, Pages 17-25

  Pai, Amy Barton ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

bioequivalence; chronic kidney disease; intravenous iron; nanoparticles

Indexed keywords

IRON DERIVATIVE; IRON NANOPARTICLE; IRON SACCHARATE; ANTIANEMIC AGENT; FERRIC ION; IRON; NANOPARTICLE; SACCHARIC ACID;

BIOEQUIVALENCE; CHEMISTRY; DRUG FORMULATION; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; SAFETY; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; FERRIC COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; IRON; NANOPARTICLES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 85039871953     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13461     Document Type: Review

References (57)

1. Hirth, R.A., M.N. Turenne, J.R. Wheeler, et al. 2013. The initial impact of Medicare's new prospective payment system for kidney dialysis. Am. J. Kidney Dis. 62: 662–669.
2. Charytan, D.M., A.B. Pai, C.T. Chan, et al. 2015. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 26: 1238–1247.
3. Besarab, A., W.K. Bolton, J.K. Browne, et al. 1998. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339: 584–590.
4. Pfeffer, M.A., E.A. Burdmann, C.Y. Chen, et al. 2009. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361: 2019–2032.
5. Singh, A.K., L. Szczech, K.L. Tang, et al. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355: 2085–2098.
6. Drueke, T.B., F. Locatelli, N. Clyne, et al. 2006. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355: 2071–2084.
7. Centers for Medicare & Medicaid Services (CMS), HHS, 2011. Medicare Program; end-stage renal disease prospective payment system. Final Rule. Fed Regist. 76: 70228–70316.
8. Bailie, G.R., M. Larkina, D.A. Goodkin, et al. 2015. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 87: 162–168.
9. DOPPS Practice Monitor. 2014. Arbor Research Collaborative for Health.
10. Toblli, J.E., G. Cao, L. Oliveri, et al. 2011. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung 61: 399–410.
11. Toblli, J.E., G. Cao, L. Oliveri, et al. 2012. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy Drug Targets 11: 66–78.
12. Kuo, K.L., S.C. Hung, T.S. Lee, et al. 2014. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J. Am. Soc. Nephrol. 25: 2596–2606.
13. Danielson, B.G. 2004. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. 15(Suppl. 2): S93–S98.
14. ®), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78: 480–491.
15. Duncan, R. & R. Gaspar. 2011. Nanomedicine(s) under the microscope. Mol. Pharm. 8: 2101–2141.
16. Stein, J., A. Dignass & K.U. Chow. 2012. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 28: 241–243.
17. Wu, X., Y. Tan, H. Mao & M. Zhang. 2010. Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int. J. Nanomed. 5: 385–399.
18. Pai, A.B., J.C. Nielsen, A. Kausz, et al. 2010. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin. Pharmacol. Ther. 88: 237–242.
19. Henderson, P.A. & R.S. Hillman. 1969. Characteristics of iron dextran utilization in man. Blood 34: 357–375.
20. U.S. Food and Drug Administration. 2013. Draft guidance on iron sucrose. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm297630.pdf. Accessed June 12, 2017.
21. European Medicines Agency. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922.pdf. 2015. Accessed June 12, 2017.
22. Barrow, M., A. Taylor, J. García Carrión, et al. 2016. Co-precipitation of DEAE-dextran coated SPIONs: how synthesis conditions affect particle properties, stem cell labelling and MR contrast. Contrast Media Mol. Imaging 1: 362–370.
23. Yang, Y., R.B. Shah, P.J. Faustino, et al. 2010. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J. Pharm. Sci. 99: 142–153.
24. Lee, E.S., B.R. Park, J.S. Kim, et al. 2013. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 29: 141–147.
25. Toblli, J.E., G. Cao & M. Angerosa. 2015. The induction of oxidative/nitrosative stress, inflammation, and apoptosis by a ferric carboxymaltose copy compared to iron sucrose in a non-clinical model. J. Clin. Diagn. Res. 9: FF08–FF12.
26. Toblli, J.E., G. Cao, L. Olieveri, et al. 2009. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 59: 176–190.
27. Toblli, J.E., G. Cao & M. Angerosa. 2015. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator. Biometals 28: 279.
28. Pai, A., D. Meyer, B. Bales, et al. 2017. Performance of redox active and chelatable iron assays to determine labile iron release from intravenous iron formulations. Clin. Transl. Sci. 10: 194–200.
29. Cabantchik, Z.I. 2014. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front. Pharmacol. 5: 45.
30. Pai, A.B., A.V. Boyd, C.R. McQuade, et al. 2007. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and sucrose in patients undergoing hemodialysis. Pharmacotherapy 27: 343–350.
31. Balakrishnan, V.S., M. Rao, A.T. Kausz, et al. 2009. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39: 489–496.
32. Tucker, P.S., V.J. Dalbo, T. Han, et al. 2013. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 18: 103–115.
33. Fishbane, S., A. Mathew & N.D. Vaziri. 2014. Iron toxicity: relevance for dialysis patients. Nephrol. Dial. Transplant. 29: 255–259.
34. Johnson, A.C., K. Becker & R.A. Zager. 2010. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am. J. Physiol. Renal. Physiol. 299: F426–F435.
35. Gupta, A., J. Zhuo, J. Zha, et al. 2010. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol. 11: 16.
36. Zager, R.A., A.C. Johnson, S.Y. Hanson, et al. 2002. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am. J. Kidney Dis. 40: 90–103.
37. Lim, C.S. & N.D. Vaziri. 2004. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 65: 1802–1809.
38. Parkkinen, J., L. von Bonsdorff, S. Peltonen, et al. 2000. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol. Dial. Transplant. 15: 1827–1834.
39. Barton Pai, A., M.P. Pai, J. Depczynski, et al. 2006. Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am. J. Nephrol. 26: 304–309.
40. Collins, A.J., J. Ebben, J.Z. Ma, et al. 1998. Intravenous iron dosing patterns and mortality [abstract]. J. Am. Soc. Nephrol. 9: 205A.
41. Feldman, H.I., M. Joffe, B. Robinson, et al. 2004. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 15: 1623–1632.
42. Kshirsagar, A.V., J.K. Freburger, A.R. Ellis, et al. 2013. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 8: e78930.
43. Teehan, G.S., D. Bahdouch, R. Ruthazer, et al. 2004. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin. Infect. Dis. 38: 1090–1094.
44. Brookhart, M.A., J.K. Freburger, A.R. Ellis, et al. 2013. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J. Am. Soc. Nephrol. 24: 1151–1158.
45. Winkelmayer, W.C., B.A. Goldstein, A.A. Mitani, et al. 2017. Safety of intravenous iron in hemodialysis: longer-term comparisons of iron sucrose versus sodium ferric gluconate complex. Am. J. Kidney Dis. 69: 771–779.
46. Brookhart, M.A., J.K. Freburger, A.R. Ellis, et al. 2016. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am. J. Kidney Dis. 67: 119.
47. Martin-Malo, A., A. Merino, J. Carracedo, et al. 2012. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27: 2465–2471.
48. Pai, A.B., C. McQuade, J. Olp, et al. 2011. Non-transferrin bound iron (NTBI), cytokine activation and intracellular reactive oxygen species generation in hemodialysis (HD) patients receiving iron dextran (ID) or iron sucrose (IS). Biometals 24: 603–613.
49. Zheng, N., D.D. Sun, P. Zou, et al. 2017. Scientific and regulatory considerations for generic complex drug products containing nanomaterials. AAPS J. 19: 619–631.
50. Elford, P., J. Bouchard, L. Jaillet, et al. 2013. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. J. Pharmacol. Toxicol. Methods 68: 374–383.
51. Slotki, I. & Z.I. Cabantchik. 2015. The labile side of iron supplementation in CKD. J. Am. Soc. Nephrol. 26: 2612–2619.
52. Zhang, X., N. Zheng, R.A. Lionberger, et al. 2013. Innovative approaches for demonstration of bioequivalence: the US FDA perspective. Ther. Deliv. 4: 725–740.
53. Macdougall, I.C., A.J. Bircher, K. Eckardt, et al. 2016. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 89: 28–39.
54. Knoeff, J., B. Flumann & S. Muhlebach. 2017. Medication practice in hospitals: are nanosimilars evaluated and substituted correctly. Eur. J. Hosp. Pharm. https://doi.org/10.1136/ejhpharm-2016-001059.
55. Spicher, K., S. Brendler-Schwaab, C. Schlösser, et al. 2015. Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Regul. Toxicol. Pharmacol. 73: 65–72.
56. Rottembourg, J., A. Kadri, E. Leonard, et al. 2011. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 26: 3262–3267.
57. Agüera, M.L., A. Martin-Malo, M.A. Alvarez-Lara, et al. 2015. Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis. PLoS One 10: e0135967.